Prognostic factors and oncological outcomes of ovarian yolk sac tumors: a retrospective multicentric analysis of 99 cases.

Authors:
Gokhan Boyraz
Gokhan Boyraz
Hacettepe University Faculty of Medicine
Turkey
Yasin Durmus
Yasin Durmus
Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital
Irfan Cicin
Irfan Cicin
Trakya University
Turkey
Oguzhan Kuru
Oguzhan Kuru
Kanuni Sultan Suleyman Teaching and Research Hospital
Turkey
Dr. Gunsu Kimyon Comert, MD
Dr. Gunsu Kimyon Comert, MD
Etlik Zubeyde Hanim Women’s Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Department of Gynecologic Oncology, Ankara, Turkey
Gynecology-Oncology Surgeon
Gynecology&Oncology;
Ankara, --- Select One --- | Turkey
Hanifi Şahin
Hanifi Şahin
Başkent University School of Medicine

Arch Gynecol Obstet 2019 Jul 13;300(1):175-182. Epub 2019 Apr 13.

Division of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Etlik, 06010, Ankara, Turkey.

Purpose: To investigate the clinico-pathological prognostic factors and treatment outcomes in patients with ovarian yolk sac tumors (YST).

Methods: A multicenter, retrospective department database review was performed to identify patients with ovarian YST who underwent surgery between 2000 and 2017 at seven Gynecologic Oncology Centers in Turkey.

Results: The study group consisted of 99 consecutive patients with a mean age of 23.9 years. While 52 patients had early stage (stage I-II) disease, the remaining 47 patients had advanced stage (stage III-IV) disease. The uterus was preserved in 74 (74.8%) of the cases. The absence of gross residual disease following surgery was achieved in 76.8% of the cases. Of the 54 patients with lymph node dissection (LND), lymph node metastasis was detected in 10 (18.5%) patients. Of the 99 patients, only 3 patients did not receive adjuvant therapy, and most of the patients (91.9%) received BEP (bleomycin, etoposide, cisplatin) chemotherapy. Disease recurred in 21 (21.2%) patients. The 5-year disease-free survival (DFS) and overall survival (OS) in the entire cohort were 79.2% and 81.3%, respectively. In multivariate analysis, only residual disease following initial surgery was found to be significantly associated with DFS and OS in patients with ovarian YST (p = 0.026 and p = 0.001, respectively).

Conclusions: Our results demonstrate the significance of achieving no visible residual disease in patients with ovarian YST. Fertility-sparing approach for patients with no visible residual disease affected neither DFS nor OS. Although high lymphatic involvement rate was detected, the benefit of LND could not be demonstrated.

Download full-text PDF

Source
http://link.springer.com/10.1007/s00404-019-05160-6
Publisher Site
http://dx.doi.org/10.1007/s00404-019-05160-6DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
July 2019
8 Reads
1.279 Impact Factor

Publication Analysis

Top Keywords

patients ovarian
16
residual disease
16
patients
14
ovarian yst
12
yolk sac
8
patients patients
8
sac tumors
8
visible residual
8
prognostic factors
8
stage stage
8
ovarian yolk
8
lymph node
8
disease
7
ovarian
5
185% patients
4
patients receive
4
node metastasis
4
metastasis detected
4
detected 185%
4
919% received
4

Similar Publications